Literature DB >> 16226036

A novel "reverse screening" to identify refolding additives for activin-A.

Daisuke Ejima1, Kunio Ono, Kouhei Tsumoto, Tsutomu Arakawa, Yuzuru Eto.   

Abstract

A general approach for refolding recombinant proteins from inclusion bodies (IBs) is to screen conditions, that facilitate a conversion of unfolded to folded structure and minimize a conversion of unfolded to misfolded and aggregated structures. In this simplified model, such conditions may be those that stabilize the native protein and/or reduce aggregation. In this paper, a novel screening approach, termed reverse screening, was developed using a native activin. Activin-A, a member of transforming growth factor beta superfamily, is a homodimeric protein with nine disulfide bonds. We examined partial unfolding process of native activin-A dissolved in a buffer containing moderate concentrations of denaturant and reducing reagent (i.e., 1.5 M urea and 0.2 mM dithiothreitol). The recovery of the protein was followed by reverse-phase high performance chromatography analysis. Without additives, activin-A showed about 60% loss of the protein due to aggregation after 12-h incubation in the above condition. We then tested various additives for their effects on the recovery after partial unfolding. One of these additives, sodium taurodeoxycholate (TDCA), greatly increased recovery and suppressed aggregation of the protein. These additives were then tested for refolding activin-A from IBs. TDCA among others is proved to be a highly effective refolding additive. These results strongly suggest that reverse screening using native proteins, if available, may be another approach to discovering effective refolding additives.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226036     DOI: 10.1016/j.pep.2005.08.013

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  7 in total

Review 1.  Approaches for the generation of active papain-like cysteine proteases from inclusion bodies of Escherichia coli.

Authors:  Chunfang Ling; Junyan Zhang; Deqiu Lin; Ailin Tao
Journal:  World J Microbiol Biotechnol       Date:  2015-03-20       Impact factor: 3.312

2.  Trans-cyclohexanediamines prevent thermal inactivation of protein: role of hydrophobic and electrostatic interactions.

Authors:  Atsushi Hirano; Hiroyuki Hamada; Kentaro Shiraki
Journal:  Protein J       Date:  2008-06       Impact factor: 2.371

3.  Production, Isolation, and Structural Analysis of Ligands and Receptors of the TGF-β Superfamily.

Authors:  Tao Huang; Andrew P Hinck
Journal:  Methods Mol Biol       Date:  2016

4.  Correlation between thermal aggregation and stability of lysozyme with salts described by molar surface tension increment: an exceptional propensity of ammonium salts as aggregation suppressor.

Authors:  Atsushi Hirano; Hiroyuki Hamada; Tatsunori Okubo; Takumi Noguchi; Hiroki Higashibata; Kentaro Shiraki
Journal:  Protein J       Date:  2007-09       Impact factor: 2.371

5.  Designer TGFβ superfamily ligands with diversified functionality.

Authors:  George P Allendorph; Jessica D Read; Yasuhiko Kawakami; Jonathan A Kelber; Michael J Isaacs; Senyon Choe
Journal:  PLoS One       Date:  2011-11-04       Impact factor: 3.240

6.  TGFBR3L is an inhibin B co-receptor that regulates female fertility.

Authors:  Emilie Brûlé; Ying Wang; Yining Li; Yeu-Farn Lin; Xiang Zhou; Luisina Ongaro; Carlos A I Alonso; Evan R S Buddle; Alan L Schneyer; Chang-Hyeock Byeon; Cynthia S Hinck; Natalia Mendelev; John P Russell; Mitra Cowan; Ulrich Boehm; Frederique Ruf-Zamojski; Michel Zamojski; Cynthia L Andoniadou; Stuart C Sealfon; Craig A Harrison; Kelly L Walton; Andrew P Hinck; Daniel J Bernard
Journal:  Sci Adv       Date:  2021-12-15       Impact factor: 14.957

7.  MB109 as bioactive human bone morphogenetic protein-9 refolded and purified from E. coli inclusion bodies.

Authors:  Mario Meng-Chiang Kuo; Phuong Hong Nguyen; Yun-Hui Jeon; Subin Kim; So-Mi Yoon; Senyon Choe
Journal:  Microb Cell Fact       Date:  2014-02-24       Impact factor: 5.328

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.